A Systematic Review of Clinical Trials Focusing on Various Therapies to Treat Follicular Lymphoma
Kavinharish Thirumurugan
26/10/2026
Follicular lymphoma (FL) is a rare type of blood cancer that is rather challenging to diagnose at earlier stages. When detected at later stages of development, the treatment of FL will be much more difficult and less effective. In comparison, when the disease is diagnosed on time, cancer often responds well to treatment and generally can be managed; however, treatments for FL, regardless of when it’s noticed, are generally volatile and risky, indicating the need for more effective and safe treatments. This paper reviews potential therapies for FL by analyzing clinical trial data of Chimeric Antigen Receptor T-cell therapies (CAR T-cell therapies), enzyme inhibitors, immunotherapies, and combination treatments. CAR T-cell therapies showed high response rates with strong efficacy but were associated with harmful side effects such as cytokine release syndrome (CRS). Similarly, immunotherapies were found to be effective, but they also showed risks of CRS. Enzyme inhibitors and combination therapies displayed several benefits of efficacy; even so, it also was affiliated with the risk of side effects. Many of these therapies, although promising, show significant safety risks, and thus, the need for additional research in developing safer and more effective treatments for FL is of great importance.
